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Background. A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely administered
at the age of 65, has limited effectiveness, and revaccination induces attenuated antibody responses. It is not known
whether pneumococcal polysaccharide-protein conjugated vaccines (PCV), although highly effective in infants,
offer any immunological advantages over 23vP in adults.
Methods. We immunized adults with schedules combining both PCV and 23vP and investigated B-cell
responses to establish whether PCV7 (a 7-valent PCV) induced T-dependent responses in adults, to assess the role
of memory B cells in 23vP-induced antibody hyporesponsiveness, and to identify the B-cell subtypes involved.
Results. A single dose of PCV7 induced signiﬁcant increases in serotype-speciﬁc memory B-cell populations in
peripheral blood indicating a T-dependent response. Conversely, immunization with 23vP resulted in a decrease in
memory B-cell frequency. Furthermore, memory B-cell responses to subsequent immunization with PCV7, when
given after 23vP, were attenuated. Notably, B1b cells, a subset important in protecting mice against pneumococci,
were also depleted following immunization with 23vP in humans.
Conclusions. This study indicates that PCV7 may have an immunological advantage over 23vP in adults and
that 23vP-induced depletion of memory and B1b-cell subsets may provide a basis for antibody hyporesponsiveness
and the limited effectiveness of 23vP.
Clinical Trials Registration. ISRCTN: 78768849.
Pneumococcal infection is a leading cause of mor-
bidity and mortality in the elderly [1]. In the United
States and the United Kingdom a polysaccharide
vaccine covering 23 pneumococcal serotypes (23vP) is
used routinely at the ageof 65.However, meta-analyses
show that 23vP has limited effectiveness against in-
vasive pneumococcal disease [2]. Some reports suggest
that protection is short-lived, which is in keeping
with the rapid waning of antibody concentrations
from the peak concentrations measured 1 month
after vaccination [3–5]. The utility of additional doses of
23vP to sustain immunity in the elderly is limited, as
antibody concentrations after subsequent doses of 23vP
are similar or lower than after primary vaccination.
This phenomenon, which has been termed ‘‘hypo-
responsiveness,’’ has also been described following
meningococcal polysaccharide vaccines [6, 7]. We
have proposed that hyporesponsiveness is due to the
depletion of the peripheral memory B-cell pool by
plain polysaccharide antigens that drive memory
B cells into terminal differentiation, without re-
plenishing the memory B-cell pool, but there is no
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pneumococcal vaccines or in the elderly population [8].
Polysaccharide antigens are postulated to stimulate splenic
marginal zone B (MZB) cells, which do not mature until the
second year of life [9]; therefore, the puriﬁed polysaccharide
contained in 23vP, a T-independent antigen, is poorly immu-
nogenic in young children. Chemical conjugation of pneumo-
coccal polysaccharide to a carrier protein creates a T-dependent
vaccine (pneumococcal conjugate vaccine [PCV]) that generates
higher afﬁnity antibodies, immunological memory, and induces
responsiveness to booster doses of vaccine, resulting in a vaccine
that is both immunogenic and highly effective from early in-
fancy [10]. Because the splenic marginal zone is immature in
early life, MZB cell responses arenot present,and itis postulated
that the conjugated polysaccharides in PCV are processed by the
follicular origin (FO) B cells at that age [11]. Despite the im-
munological advantages of PCV in early childhood, both PCV7
(a 7-valent PCV) and 23vP induce similar antibody concen-
trations in adults [12], and it is therefore unclear whether the
conjugate vaccine has any immunological advantage over 23vP
or whether the same B-cell subsets are involved in the response.
In the present study, we enumerated the frequency and
identiﬁed the phenotype of the serotype-speciﬁc B cells in the
peripheral blood of older adults following immunization with
combinations of PCV7 and 23vP to investigate the effects of
these vaccines on B-cell populations.
METHODS
Participants and Study Design
A phase 4, open-label, randomized, parallel trial was conducted
in Oxford, United Kingdom, involving adults aged 50–70 years,
as described elsewhere [12]. Written informed consent was ob-
tained from the participants before enrollment. Ethical approval
was obtained from the Oxfordshire Research Ethics Committee
06/Q1604/121.
Participants were randomized to receive PCV7-PCV7-23vP
or 23vP-PCV7-PCV7 or PCV7-23vP-PCV7 with vaccines given
6 months apart. Blood was sampled prior to and after (7 days
and 1 month) vaccination.
Vaccines
The pneumococcal conjugate vaccine (PCV7; Prevenar, Wyeth
Vaccines; batch numbers ND05370, NE31130, NG12460) con-
sisted of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C,
19F, and 23Fsaccharides (2 lg of all serotypes except 4 lgo f6 B )
conjugated to a CRM197 carrier protein with aluminum phos-
phate as an adjuvant. The pneumococcal plain polysaccharide
vaccine (23vP; Pneumovax II, Aventis Pasteur MSD; batch
numbers 20218, 25305, 22995) consisted of S. pneumoniae
s e r o t y p e s1 ,2 ,3 ,4 ,5 ,6 B ,7 F ,8 ,9 N ,9 V ,1 0 A ,1 1 A ,1 2 F ,1 4 ,
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F (25 lg for each
serotype). Both vaccines were given as 0.5-mL solutions in-
tramuscularly using a 23G 25-mm needle.
B-Cell Enzyme-Linked Immunosorbent Spot Assay
Preparation of Peripheral Blood Mononuclear Cells
A maximum volume of 18 mL of heparinized blood was avail-
able for the separation of peripheral blood mononuclear
cells (PBMCs). The blood was diluted 1:2 with RPMI 1640
(Sigma-Aldrich) to which penicillin-streptomycin solution
(Sigma-Aldrich) and 200 mM L-glutamine (Sigma-Aldrich)
had been added at a dilution of 1:100 (complete medium).
PBMCs were then separated by density gradient centrifugation
over Lymphoprep (Axis-Shield). PBMCs were washed once in
complete medium before being seeded directly onto enzyme-
linked immunosorbent spot assay (ELISpot) plates or being
placed into cell culture.
Preparation of ELISpot Plates
Multiscreen IP 96-well ﬁlter plates, (Millipore) were coated with
either 10lg/mL (serotypes 4,9V, 14, 18C, and 19F) or 20 lg/mL
(serotypes6Band 23F)ofpuriﬁed pneumococcal polysaccharide
(LGC Promochem) conjugated to methylated human albumin
(UK National Institute for Biological Standards and Control),
10 lg/mL diphtheria toxoid tetanus toxoid (Statens Serum
Institut) or phosphate-buffered saline (PBS) alone. Prior to
cells being seeded onto the plates, all wells were blocked with
newborn bovine serum (NBBS).
Detection of Plasma Cells
Washed PBMCs were seeded onto ELISpot plates with 200 000
cells placed in each well; at least 3 wells for each antigen were
seeded. The plates were incubated overnight at 37Ci n5 %
carbon dioxide and 95% humidity. The cells were washed in
PBS-Tween and bound immunoglobulin G (IgG) antibody was
detected using an alkaline phosphatase conjugate and AP-
conjugate substrate kit (nitroblue tetrazolium 1 5-bromo-4-
chloro-3-indolyl phosphate in dimethylformamide; Bio-Rad).
Detection of Memory B Cells
PBMCs prepared as described above were resuspended in RPMI
with 10% NBBS and placed in 96-well round bottom culture
plates (Costar) at a ﬁnal concentration of 2 3 10
6 cells/mL. The
cells were cultured with an additional 100 lL of RPMI with 10%
NBBS, and (ﬁnal well concentrations) Staphylococcus aureus
Cowan strain (SAC) at 1:5000 dilution of the Pansorbin cell
suspension (Calbiochem-Novabiochem), pokeweed mitogen at
1:6000 dilution (Sigma-Aldrich), and CpG oligonucleotide at
a 1:40 dilution (ODN-2006; TCG-TCG-TTT-TGT-CGT-TTT-
GTC-GTT, InvivoGEN). The cells were incubated for 6 days
at37C in 5% carbon dioxide and 95% humidity,after which time
they were washed in PBS-Tween and seeded onto ELISpot plates
and processed as described above for the detection of plasma cells.
ELISpot Counting
Spots were counted using the AID ELISpot Reader ELR02 and
software version 3.3 (Cadama Medical). Identical settings were
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and any artifacts removed; the operator was blinded to the
sample being counted.
Phenotypic Analysis by Flow Cytometry
B cells were puriﬁed (94%–98%) from fresh PBMCs, following
Fc Receptor (FcR) blocking, using anti-CD19 microbeads and
AutoMACS (Miltenyi Biotec). The B-cells were labeled with
combinations of anti-CD21–ﬂuorescein isothiocyanate (FITC)
(Serotec), anti–CD5-APC, anti–CD23-PE, anti–CD27-PE, anti–
IgM-PECy5, and anti–IgG-PE (BD Biosciences). Speciﬁcity of
the B-cells was determined using biotinylated pneumococcal
capsular polysaccharides labeled with anti–Biotin-FITC (Mil-
tenyi Biotec). The cell data were acquired and analyzed using
a BD FACSCalibur and CellQuest software.
Plasma cell populations were identiﬁed by intracellular la-
beling of CD19-sorted B cells for immunoglobulin (Ig). B-cells
were permeabilized using BD Cell Fix/Perm Kit (BD Bio-
sciences). The population was identiﬁed using CD38-PE
(hi),
CD20-APC
(lo), CD19-PECy5
(1) and IgA, IgG, or IgM-FITC
(1).
Statistical Analysis
The primary outcome was based on antibody response, which
has been published separately (12). The secondary outcomes
relating to B-cells were to characterize the phenotype of the
B-cells involved in the response to immunization with 23vP
and PCV7; to assess the memory B-cell response to a single
dose of PCV7 and 23vP; and to assess the effect of prior im-
munization with 23vP on the memory B-cell response to 1 or 2
doses of PCV. The sample size for memory B-cell analysis was
determined by 2 interim analyses, the ﬁrst performed after the
ﬁrst 150 participants completed the second visit and the second
after the same participants had completed the fourth visit.
Phenotypic analysis was performed on blood sampled at the
fourth study visit when sufﬁcient blood was available. A subset
of participants who agreed to an additional venipuncture had
a blood sample drawn 7 days after their last vaccination. The ﬁnal
data set available was determined by the practical constraints in-
cluding the volume of blood collected and the assay failure.
B-cell numbers were log-transformed to obtain normality for
analysis, but untransformed numbers with median values are
presented as descriptive data. Analyses were performed by
adjusting for baseline frequencies. The P values were adjusted
for multiple comparisons using the false discovery rate method
[13]. Signiﬁcance was set at a , .05%. Data were analyzed using
Stata software, version 9.1 (StataCorp).
RESULTS
Samples from at least 150 individuals at each study time point
were obtained for B-cell studies. Approximately 1050 in-
dividual samples were analyzed. In addition, 18 samples were
obtained at 7 days after the ﬁnal vaccination for analysis of
plasma cell response.
Memory B Cells After a Single Dose of 23vP or PCV7
Prior to vaccination, 86% of participants evaluated had de-
tectable memory B-cells that secreted antibody to at least 1 of
the 7 serotypes tested, despite no history of previous pneu-
mococcal vaccination. Twenty-eight days after vaccination there
was an increase in the frequency of memory B-cells detected
in those who had received PCV7. In contrast, participants who
received 23vP showed a decrease in the memory B-cell frequency
from baseline (Figure 1A). Six months after vaccination, the
memory B-cell frequency in those who had received PCV7
returned to baseline, whereas in those who had received 23vP
a further decline was shown (Figure 1B).
Memory B-Cell Responses After Primary Vaccination With 23vP
or PCV7
Memory B-cell (MBC) responses to PCV7 given 6 months
after 23vP were signiﬁcantly lower than after a single dose of
PCV7 for all serotypes except serotype 14 (Figure 1C), but
recovery of MBC levels was seen after the second dose of PCV7
(Figure 1D). When 23vP was administered after 1 or 2 doses of
PCV7, a decrease in MBC was recorded.
Phenotypic Analysis
The proportion of pneumococcal polysaccharide (PnPs),
speciﬁc MZB (CD19
1CD20
1CD27
hiIgM
hi), and FO B-cells
(CD19
1CD20
1CD27
hiIgM
lo)i np e r i p h e r a lb l o o d1m o n t ha f t e r
the second vaccination in the series did not differ between
the 2 groups (PCV7-PCV7, n 5 24 vs 23vP-PCV7, n 5 19;
Figure 2A). However, there were fewer PnPs-speciﬁc switched
MBCs (CD19
1CD20
1CD27
hiIgM
2) in the 23vP-PCV7 group
than in the PCV7-PCV7 group. There were also fewer PnPs-
speciﬁc cells of the B1-cell phenotype (CD19
1CD20
1
CD27
2IgM
hi) in the 23vP-PCV7 group (Figure 2A). The B1-cell
subset was further analyzed for expression of CD5 to differen-
tiate between B1a (CD5
int) and B1b (CD5
neg)c e l l s( Figure 2B).
The B1a population (CD19
1PnPs
1CD5
intCD27
2IgM
hi)d i d
not differ between the 2 groups. However, fewer B1b-cells
(CD19
1PnPs
1CD5
negCD27
2IgM
hi) were seen in those who
had received 23vP-PCV7 (n 5 8; Figure 2B).
Inorder to assessthe early T-independent versusT-dependent
B-cell response, blood was sampled 7 days following the ﬁnal
vaccine in each group, either PCV (23vP-PCV-PCV, n 5 5) or
23vP (PCV-PCV-23vP, n 5 8) (Figure 2C). When either 23vP
or PCV7 was given as the ﬁnal dose in the series, the production
of MZB cells (R3-CD21
hiCD23
lo) was similar between the
groups (Figure 2C). However, PCV7 induced a greater number
of FO B-cells (R4-CD21
loCD23
hi), the putative precursors of
switched MBC (Figure 2C). Conversely, 23vP induced a sig-
niﬁcantly higher percentage of B1-cells (R5-CD21
loCD23
lo;
P 5 .0062, Figure 2C).
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There were signiﬁcantly higher frequencies of intracellularly la-
beled IgG
1,I g A
1,a n dI g M
1 plasma cells(CD19
1CD20
2CD38
hi)
following a ﬁnal vaccine dose of 23vP than PCV7 (P 5 ,.0001,
P 5 ,.0001, and P 5 .0288, respectively) (Figure 3A). Simi-
larly, the total number of IgG-, IgA-, and IgM-secreting plasma
cells (ASCs) in peripheral blood on day 7 was signiﬁcantly
higher after boosting with 23vP when compared with PCV7
(P 5 .051, P 5 .0023, and P 5 .051, respectively; Figure 3B).
DISCUSSION
This is the ﬁrst study to our knowledge to demonstrate that
pneumococcal conjugate and polysaccharide vaccines produce
distinct B-cell responses in adults and to establish potential
cellular mechanisms responsible for polysaccharide-induced
hyporesponsiveness.
The detection of memory B-cells following immunization
with PCV7 in older adults in this study indicates that this vac-
cine induces a T-dependent response in this age group and
therefore may have an immunological advantage over 23vP,
which does not. It may be that repeated doses of PCV7 allow
immunity to be sustained. Although the use of repeated doses of
23vP in adults to sustain immunity cannot be supported owing
to the induction of attenuated responses to subsequent pneu-
mococcal vaccine, it is likely that carrier protein–derived pep-
tides, presented in the context of major histocompatibility
complex class II by B-cells to cognate T cells, are responsible for
driving theresponsethroughgerminal centers, resulting inMBC
production. It has also been postulated that conjugation of
Figure 1. Downregulation of memory B cells by the 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) and subsequent recovery by
a 7-valent pneumococcal conjugate vaccine (PCV7). A, Participants were vaccinated with either 1 dose of 23vP (red) or 1 dose of PCV7 (blue). Calculation
of the mean change in serotype specific memory B-cells (MBC) from before to after vaccination showed an increase for all serotypes after PCV7 but
a decrease after 23vP. MBC responses significantly differed between the vaccines for serotypes 4 (P 5 .045), 9V (P 5 .042), 18C (P 5 .045), 19F
(P 5.035), and 23F (P5 .0149) B, The decline in MBCs seen after 23vP continued for 6 mo after vaccination. C, When participants who had received 23vP
were given a dose of PCV7 6 mo later, there was an increase in their MBCs, but the number of MBCs after 23vP-PCV7 (green) remained lower than after
a single dose of PCV7 (blue) alone. Horizontal bar represents median value, and each spot represents 1 sample (serotype 4, P 5 .038; serotype 6B,
P 5 .006; serotype 9V, P 5 .003; serotype 14, P 5 .0009; serotype 18C, P 5 .007; serotype 19F, P 5 .008; serotype 23F, P 5 .0009). D, After a second
dose of PCV7, memory B-cell numbers recovered to baseline values. All comparisons were made using analysis of covariance and P values adjusted using
a false recovery method. Abbreviation: PBMCs, peripheral blood mononuclear cells.
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[14] limiting the T-independent stimulus through the B-cell
receptor, leading to the preferential selection of B-cells for
entry into germinal centers rather than driving extrafollicular
proliferation. A recent study, however, during which older
adults wererevaccinated with 23vP10 years aftertheir lastdose,
demonstrated that the antibody response to 23vP was preserved
and was not hyporesponsive [15]. We propose that this relates
to recovery of memory B-cells over time.
The lack of memory B-cell production following immuniza-
tion with 23vP is consistent with its T-independent nature.
Polysaccharide antigens are believed to predominantly activate
MZB cells in extrafollicular reactions that do not lead to MBC
induction. In this study it was demonstrated that immunization
with 23vP resulted not only in a lack of MBC induction but
a decrease in the frequency of peripheral MBCs compared with
prevaccination levels. This ﬁnding is in keeping with the hy-
pothesis that polysaccharide antigens drive preexisting switched
Figure 2. Depletion of polysaccharide-specific B1b-cells in 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP)–primed individuals.
A, Subjects were randomized to receive 7-valent pneumococcal conjugate vaccine (PCV7)-PCV7 (group 1; blue circles,n5 24) or 23vP-PCV7 (group 2; red
circles,n5 19). CD19
1 purified B-cells were obtained 28 d after the second vaccine dose. Following gating on CD20
1 pneumococcal polysaccharide
(PnPs
1) B-cells, the proportions of naive (CD27
2IgM
lo), B1 (CD27
2IgM
hi), MZB (CD27
hiIgM
hi), FO (CD27
1IgM
lo), and switched memory B-cells
(CD27
1IgM
2) that bound PnPs–fluorescein isothiocyanate (FITC) were determined. The data in the graph show the percentage of PnPs-specific B-cells within
eachof thesubsets foreach vaccine group,andthebarrepresents the median. B, B1b-cell but not B1a-cell frequency was reduced in23vP-primed individuals.
Purified CD19
1 B-cellswerelabeledwithanti-CD5,andthefrequencyofB1a(CD19
1PnPs
1IgM
hiCD27
2CD5
int)vsB1b(CD19
1PnPs
1IgM
hiCD27
2CD5
neg)ce l ls
were determined for group 1 (blue,n5 9) and group 2 (n 5 8). The data represent the percentage of CD19
1PnPs
1CD27
2IgM
hi B cells that were CD5
int or
CD5
neg, and the bar shows the median (CD5 bright cells were residual T cells remaining after the sort). C, Boosting with 23vP induced a large B1-cell
efflux into peripheral blood on day 7: PCV7-primed individuals received a 23vP booster (group 1: n 5 8, blue circles) whereas those primed with 23vP-
PCV7 were boosted with PCV7 (group 2: n 5 5, red circles). Purified CD19
1 B cells were then obtained on day 7 postboost, and the frequency of CD19
1
marginal zone B-cells (CD23
2CD21
hi), follicular origin B-cells (CD23
1CD21
2), and B1 cells (CD23
2CD21
2) present in peripheral blood mononuclear cells
(PBMCs) on day 7 postboost in each group were compared. The graph represents the percentage of CD19
1 B-cells within each subset, and the line shows
the median value.
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replenish the MBC pool [8].
The depletion of the peripheral MBC pool after immuniza-
tion with 23vP may result in a lower frequency of peripheral
B-cells being available to respond to subsequent doses of pneu-
mococcal vaccine (or indeed natural antigen) as seen in this
study. This phenomenon may explain why attenuated antibody
responses are produced to subsequent doses of pneumococcal
vaccination in individuals previously immunized with 23vP.
Depletion of memory B-cells and antibody hyporesponsiveness
induced by 23vP may in part explain the limited effectiveness and
short-term immunity associated with this vaccine in the elderly
[3, 4]. These results contrast with those reported by Baxendale
et al [16], who found no differences in memory B-cell responses
between these 2 pneumococcal vaccines in adults. However,
the small sample size in the 23vP group in the previous study
and methodological differences in the in vitro B-cell assay make
it impossible to directly compare the ﬁndings. However, both
studies clearly demonstrate that adults have serotype-speciﬁc
memory B-cells detectable prior to pneumococcal immunization.
The signiﬁcanceof thelargeplasma response inducedby23vP
when given as the second vaccine in the series is not clear. It may
Figure 3. Boosting of 7-valent pneumococcal conjugate vaccine (PCV7)–primed individuals with the 23-valent unconjugated pneumococcal
polysaccharide vaccine (23vP) induced a large efflux of plasma cells 7 d postboost. Purified CD19
1 B-cells were obtained 7 d after boosting with 23vP
(group 1, blue) or PCV7 (group 2, red). A, Plasma cells were identified using the phenotype (CD19
1CD20
lo/-CD38
hi) and intracellular immunoglobulin G
(IgG), immunoglobulin A (IgA), or immunoglobulin M (IgM) expression was determined. Example density plots showing the plasma cell populations (IgG,
IgA, and IgM) for each group are given, and the graphs show the frequencies (with median) as a percentage of CD19
1 B-cells for group 1 (n 5 12) and
group 2 (n 5 18). B, B-cells isolated from some of the same individuals were also seeded directly onto enzyme-linked immunosorbent spot assay (ELISpot)
plates to detect the total number of IgG-, IgA-, and IgM-secreting cells for group 1 (n 5 7) and group 2 (n 5 5).
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high polysaccharide content. Alternatively, it may be that the
initial dose of PCV7 has led the production of MBCs meaning
that there is a greater pool of B-cells available to respond to
23vP, resulting in a large plasma cell response.
The B-cell subsets involved in the response to pneumococcal
vaccines in adults are yet to be clariﬁed. The peripheral B-cell
compartment consists of 2 main subsetsdB1 and B2cells. The
B2 subset consists of MZB cells and FO B cells (which are the
precursors to switched MBCs). Classically, polysaccharide
antigens are thought to activate MZB cells, whereas protein
antigens activate FO B cells [17, 18]. The B1 subset, less well
characterized in humans than in rodents, is believed to
originate from the fetal liver and adult bone marrow and be
involved in the early, nonadaptive phase of the immune re-
sponse [19]. In this study we demonstrate no differences in the
frequency of serotype-speciﬁc MZB cells 1 month or 7 days
after vaccination with 23vP or PCV7 when given as the second
vaccine in the series, suggesting that both vaccines are equally
able to stimulate the marginal zone subset, perhaps because
the PCV7 formulation also contains unconjugated poly-
saccharide, which is responsible for MZB-cell activation.
However, assessment of changes in the frequency of this
subset in the peripheral compartment might be an insensitive
measure as the majority of these cells are located in the spleen.
When the frequencies of switched MBCs were compared after
2 doses of vaccine, individuals who had received 23vP (23vP-
PCV7) as their primary vaccination had fewer of this cell type
than those who had received 2 doses of PCV7. This difference
may be explained by the depletion of the switched MBC
subset by 23vP or the induction of this subset by PCV7.
The latter is supported by the higher frequency of FO B
cells (the precursors to switched MBCs) detected 7 days after
vaccination with PCV7 (as the second vaccine in the series)
when compared with 7 days after 23vP (preceded by PCV7). An
unexpected ﬁnding was that in the 23vP-PCV7 group there
were also signiﬁcantly fewer cells of the B1b phenotype com-
pared with the PCV7-PCV7 group 1 month after the second
vaccination. In addition, 7 days after 23vP (preceded by PCV7)
a signiﬁcantly higher percentage of B1-cells were detected in
comparison to the PCV7-PCV7 group. These data suggest that
23vP may speciﬁcally interact with the B1-cell subset leading to
their activation as antibody-secreting cells and subsequent de-
pletion, a ﬁnding that to our knowledge has not previously
been described in humans. B1b-cells were found previously to
play an essential role in the protection of mice against blood-
borne pathogens such as S. pneumoniae and Borrelia hermsii
[20, 21]. B1b-cells are part of a self-replenishing population
that derives from low-frequency bone marrow precursors in
adult mice [22]. B1b-cells are not thought to engage in follic-
ular responses and therefore do not generate MBCs. Thus,
terminal differentiation of large numbers of B-cells from this
subset by 23vP could have a long-lasting impact on the pe-
ripheral population. This may contribute to fewer B-cells being
available to respond to subsequent antigen challenge after
vaccination with 23vP, as supported by our data.
The cellular mechanisms responsible for 23vP-induced anti-
body hyporesponsiveness have not been fully elucidated, but
using the observations outlined above, we propose a new model
incorporating B1b-cells (Figure 4A–D).
The clinical signiﬁcance of hyporesponsiveness in humans
is unknown. Antibody hyporesponsiveness or immune toler-
ance to repeated vaccination with polysaccharide antigens was
ﬁrst described in mice by Felton and Bailey in 1926 [23].
They showed that administration of large amounts of sero-
type-speciﬁc polysaccharide to mice rendered them more sus-
ceptible to infection with that serotype and unresponsiveness to
vaccination with that serotype. Moreover, the role of B1b-cells
in the protection of mice against S. pneumoniae, which we
found were depleted by 23vP, has been established [21]. These
observations in mice, taken together with our ﬁnding that
the same B-cell subsets are affected by plain polysaccharides in
humans, is of concern. The amount of polysaccharide used
for immunization has been shown to inﬂuence the induc-
tion of immune tolerance. 23vP contains at least 575 lgo f
polysaccharide, whereas PCV7 contains ,20 lg; therefore,
23vP-induced hyporesponsiveness may be related to its high
polysaccharide content. Furthermore, polysaccharide anti-
gen has been shown to persist for prolonged periods of time
in vivo [23]. Indeed, retention of pneumococcal polysaccharide
in mice has been described for up to 18 months following
immunization, depending on the serotype tested [24] and
could lead to depletion or exhaustion of the B-cell pool due to
chronic antigen stimulation. The generation of MBCs by PCV7
may potentially overcome antibody hyporesponsiveness by
expanding the B-cell pool available to respond to subsequent
antigen challenge. Despite the recovery of MBCs, depleted
by the ﬁrst dose of 23vP, using 2 doses of PCV7 antibody
responses remained attenuated during this 12-month study
[12], although recovery has been demonstrated with longer
duration between doses with group C meningococcal vaccines
for young adults [25]. However, these observations do suggest
that memory B cells, depleted by polysaccharide vaccine, could
be recovered by immunization with PCV.
In the original study from which these data were obtained, all
participants received 2 doses of PCV7 and 1 dose of 23vP over
a 12-month period [12]. The immunogenicity produced by the
3-dosevaccinescheduledidnotsigniﬁcantlyimprove onasingle
dose of PCV7. In addition to the lack of superiority, such
a schedule may have also been problematic in terms of both
compliance and cost, which need to be carefully considered
when designing vaccine schedules.
In summary, we show that PCV7 induces MBC production,
whereas 23vP causes depletion in the peripheral MBC population.
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by 23vP to subsequent vaccination, which may contribute to
the limited and poorly sustained effectiveness of the vaccine.
Induction of MBC by PCV7 provides the possibility that it
could be used in individuals previously immunized with 23vP
to overcome hyporesponsiveness, but the timing and dosing
required have not been determined. With the availability of
PCVs covering 10 and 13 serotypes, the possibility of improved
protection against pneumococcal disease in the elderly must be
explored in efﬁcacy trials as soon as possible. The data provided
in this study emphasize the immunological disadvantage of the
current vaccine,23vP,given to vastnumbersofolderadults[26].
Figure 4. Priming with 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) induces depletion of peripheral blood B1b and marginal
zone B (MZB) cells—a mechanism. The top section of each panel is a representation of the B-cell enzyme-linked immunosorbent spot assay (ELISpot) data
obtained, for each serotype in 7-valent pneumococcal conjugate vaccine (PCV7), at each point during the time course (x-axis). The middle section of each
panel describes the effects of each immunization on the B-cell compartment. The bottom sections of panels B and C show the interaction of multivalent,
high-epitope-density T-independent antigens vs low-epitope-density T-dependent antigens with a responsive B cell. A,Prior to immunization, the baseline
composition of the peripheral B-cell pool is a mix of preexisting memory B cells, B1 cells, and MZB cells that can be stimulated to form immunoglobulin G
(IgG)-ASCs following in vitro stimulation with mitogens, and these ASCs are detected in B-cell ELISpots at day 0. B, The polysaccharides in 23vP consist of
multivalent (repeating) epitopes that are able to cross-link many B-cell receptors (BCRs) ona single cell providing a strong activation signal. Thus, the high
dose of multivalent polysaccharides from 23 serotypes in 23vP may induce exhaustion of the peripheral B-cell pool by preferentially driving extrafollicular
proliferation of B1b, memory B, MZB, and naive B cells via cross-linking BCRs, inducing a large plasma cell response. The lack of T-cell recruitment and
germinal center formation prevents replenishment of the memory B-cell pool. This is demonstrated by the reduced frequency of ASCs detected in the
ELISpot 1 mo postimmunization. C, Reduced frequency of polysaccharide specific B cells is still evident 6 mo later, and a subsequent dose of PCV7 is
unable to induce increased frequencies of polysaccharide-specific B cells. The conjugated polysaccharide has reduced epitope density compared with the
plain polysaccharide and cross-links fewer BCRs. This results in a weaker signal, and thus T-cell help is required for the B cell to proliferate. This occurs in
the germinal center and results in formation of new memory B cells. However, the hyporesponsiveness observed in the ELISpot assay shows that 1 dose
of PCV7 is not enough to overcome the effects of 23vP. D, The booster dose of PCV7 induces an increase in memory B cells detected by ELISpot
demonstrating that by month 13 the hyporesponsiveness induced by 23vP has been overcome for the 7 serotypes in PCV7 and that the memory B-cell pool
has been replenished for these serotypes. Abbreviation: PMBC, peripheral blood mononuclear cell.
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